A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)

To assess the efficacy and safety of two concentrations (0.03% and 0.06%) of CD11301 gel in
the treatment of early stage CTCL (stage IA, IB, or IIA) versus placebo.

Inclusion Criteria:

- Clinical Diagnosis of CTCL stage IA, IB, or IIA with biopsy within last 3 months

- Have BSA involvement corresponding to stages IA, IB or IIA CTCL with at least 3
distinct lesions

Exclusion Criteria:

- CTCL that is stage IIB or great or stage IIA with stage N2 with >5% circulating Sezary
cells or CD8+ or large cell transformation or Progressive CTCL

- History of autoimmune disease

- Laboratory test values at screening outside of the normal range and judged clinically
significant by the investigator

- Current participation in another clinical trial of a drug or device or past
participation within 4 weeks before Baseline or subject is in exclusion period from a
previous clinical trial